Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660929 | 0.79 | ALDH1A1 (0.34) | LMNAALDH1A1SMN1; SMN2ENPP1MEN1 | |
| SCHEMBL7199405 | 0.78 | ALDH1A1 (0.39) | LMNAALDH1A1SMN1; SMN2ENPP1AGXT | |
| SCHEMBL1660315 | 0.78 | AGXT (0.33) | LMNAALDH1A1AGXTMEN1KMT2A | |
| SCHEMBL23830427 | 0.77 | MEN1 (0.33) | LMNAALDH1A1SMN1; SMN2MEN1NR2F2 | |
| SCHEMBL856076 | 0.77 | SELE (0.39) | LMNAALDH1A1SMN1; SMN2ENPP1MEN1 | |
| SCHEMBL1663003 | 0.75 | MEN1 (0.33) | LMNAALDH1A1SMN1; SMN2MEN1NR2F2 | |
| SCHEMBL10568054 | 0.73 | CYP1A2 (0.34) | LMNAALDH1A1AGXT | |
| SCHEMBL83401 | 0.72 | — | — | |
| SCHEMBL18809342 | 0.71 | PDPK1 (0.34) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6968126 | 0.69 | PDE10A (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2488514-B1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| US-4820708-A | ANTISECRETORY AGENTS; GASTROINTESTINAL DISORDERS | SMITH KLINE & FRENCH LABORATORIES (GB) | 1989-04-11 | — | — | US | disclosed |
| US-4777172-A | ANTIGASTRIC ACID SECRETORY AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-10-11 | — | — | US | disclosed |
| CN-86102398-A | The preparation method of substituted benzimidazole derivative | — | 1986-11-12 | — | — | CN | disclosed |
| EP-0198583-A1 | Heterocyclic compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | CHRNA7, CHRNA5, CHRNA1 | LMNA 3803/4885ALDH1A1 534/4885SMN1; SMN2 2734/4885 |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | LMNA 3819/4885ALDH1A1 522/4885SMN1; SMN2 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.